Antihypertensive Drugs Market to Rise Due to Increasing Proliferation of Combined Doses

Transparency Market Research Report Added "Antihypertensive Drugs Market" to its database.

Logo

Albany, NY -- (SBWire) -- 04/05/2016 --A new market research report by Transparency Market Research, titled "Antihypertensive Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023", incorporates an in-depth analysis of the market for antihypertensive drugs. The study presents an extensive evaluation on the present trends in the market along with the prime restraints and drivers impacting the growth of the market in the forecast horizon between 2015 and 2023. The report also entails the current technological developments taking place in the market for antihypertensive drugs. A review of the macro and micro factors beneficial to the already existing players as well as the emerging players also forms an integral part of this study. The vendor landscape section of the report comprises a detailed analysis of the key vendors operating in the market along with stating their top strategies.

According to the report, the increasing proliferation of combined doses, the shifting lifestyles of individuals, and the increasing levels of stress amongst people are the chief factors stimulating the growth of the market for antihypertensive drugs. On the other hand, factors such as the low rate of diagnostics and the patent expiry of key drugs including Cozaar (Merck), Diovan (Novartis), Revatio (Pfizer), Atacand (AstraZeneca), Exforge (Novartis), BIopress (Takeda), Benicar (Daiichi Sankyo), and Avapro (Sanofi-Aventis) may inhibit the growth of the market in the coming years.

The report segments the market for antihypertensive drugs on the basis of therapy area and geography.

In terms of therapy area, the report segments the market for antihypertensive drugs into calcium channel blockers (Nifedipine, Felodipine and Diltiazem), diuretics (Hydrochlorothiazide and Indapamide), angiotensin converting enzyme (ACE) inhibitors (Captopril, Lisinopril and Perindopril), angiotensin receptor blockers or ARBs (Losartan), alpha blockers (Clonidine, Guanabenz), renin inhibitors, and beta blockers vasodilators (Atenolol and Propranolol). Amongst these, the segment of diuretics holds the largest share in the market owing to them being the first line of treatment for hypertension.

Download PDF: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=7718

On the basis of geography, the market for antihypertensive drugs is segmented into Europe, North America, Latin America, the Middle East and Africa, and Asia Pacific. Amongst these, the regions of Europe and North America dominate the market. As per the World Health Organization (WHO), hypertension is the highest within Africa. Within Africa, over 40% adults have hypertension and the majority of them stay undiagnosed owing to the unaffordability of medication due to low disposable incomes.

As per the report, the prominent players operating in the market for antihypertensive drugs are Pfizer Inc., Novartis AG, Sanofi S.A, Daiichi - Sankyo, Johnson & Johnson Ltd., Merck & Co., Ranbaxy Laboratories Limited, and AstraZeneca Plc., and Lupin Limited, among others.

Contact us:
Mr. Sudip S
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

Media Relations Contact

Mr. Sudip S
Assistant Manager
Transparency Market Research
1-518-618-1030
http://www.transparencymarketresearch.com/antihypertensive-drugs-market.html

View this press release online at: http://rwire.com/678570